Abeona Therapeutics announces FDA allowance of IND for phase 1/2 clinical study
Abeona Therapeutics announced the FDA has allowed an Investigational New Drug Application for its Phase 1/2 Clinical Study with gene therapy candidate ABO-101 (AAV-NAGLU) for patients with Sanfilippo syndrome type B to be conducted at Nationwide Children's Hospital (Columbus, OH). May 24, 2016